BAAR, Switzerland--(BUSINESS WIRE)--Biopartners GmbH and LG Life Sciences Ltd (LGLS) today presented positive phase 3, placebo-controlled six month efficacy and safety data in adults with growth hormone deficiency (GHD) for LB03002, a once-a-week, sustained release recombinant human growth hormone, at the 91st annual meeting of the Endocrine Society (ENDO 09) in Washington, DC.
